WallStSmart

Brainsway Ltd (BWAY)vsMedtronic PLC (MDT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 61754% more annual revenue ($37.54B vs $60.70M). BWAY leads profitability with a 15.6% profit margin vs 13.9%. MDT trades at a lower P/E of 24.8x. MDT earns a higher WallStSmart Score of 70/100 (B).

BWAY

Buy

51

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.40

MDT

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 6.5Value: 4.7Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BWAY.

MDTOvervalued (-9.4%)

Margin of Safety

-9.4%

Fair Value

$94.02

Current Price

$102.86

$8.84 premium

UndervaluedFair: $94.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BWAY3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.4%10/10

Revenue surging 35.4% year-over-year

EPS GrowthGrowth
59.8%10/10

Earnings expanding 59.8% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

MDT5 strengths · Avg: 8.2/10
Market CapQuality
$129.18B9/10

Large-cap with strong market position

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

BWAY3 concerns · Avg: 2.3/10
Market CapQuality
$406.96M3/10

Smaller company, higher risk/reward

P/E RatioValuation
42.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.402/10

Distress zone — elevated risk

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : BWAY

The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

BWAY profiles as a growth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.57 — expect wider price swings.

BWAY is growing revenue faster at 35.4% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (70/100 vs 51/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?